Literature DB >> 16935014

Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice.

Carey J Ng1, Susan Y Hama, Noam Bourquard, Mohamad Navab, Srinivasa T Reddy.   

Abstract

Accumulating evidence suggests that the oxidative modification of low-density lipoprotein (LDL) plays an integral role in the initiation and progression of atherosclerosis. We have previously reported that human paraoxonase (PON)2 possesses antioxidant properties and is capable of preventing LDL oxidation in vitro. The objective of this study was to determine whether elevated levels of PON2 could protect against the development of atherosclerosis in vivo. Six-month-old apolipoprotein E-deficient mice (apoE(-/-)) were injected intravenously with either PBS or 3 x 10(11) particles of adenovirus expressing GFP (AdGFP) or human PON2 (AdPON2). Three weeks post-injection, lesion area was significantly lower in mice treated with AdPON2 compared to their control counterparts. Serum from AdPON2 treated mice contained significantly lower levels of lipid hydroperoxides and exhibited an enhanced potential to efflux cholesterol from cholesterol-loaded macrophages. In addition, LDL from AdPON2 treated mice was less susceptible to oxidation, while HDL from these same mice was significantly more capable of protecting LDL against oxidation. These results demonstrate for the first time that elevated levels of PON2 can enhance the efflux potential and antioxidant capacity of serum, increase the anti-inflammatory properties of HDL, and protect against the development of atherosclerosis in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16935014     DOI: 10.1016/j.ymgme.2006.07.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  26 in total

1.  Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation.

Authors:  Gerard Aragonès; Anabel García-Heredia; Marta Guardiola; Anna Rull; Raúl Beltrán-Debón; Judit Marsillach; Carlos Alonso-Villaverde; Bharti Mackness; Michael Mackness; Juan Pedro-Botet; Pedro Pardo-Reche; Jorge Joven; Jordi Camps
Journal:  J Lipid Res       Date:  2011-10-14       Impact factor: 5.922

2.  Comparative modeling of PON2 and analysis of its substrate binding interactions using computational methods.

Authors:  Subramanian Barathi; Muralidaran Charanya; Shivashanmugam Muthukumaran; Narayanasamy Angayarkanni; Vetrivel Umashankar
Journal:  J Ocul Biol Dis Infor       Date:  2011-02-09

Review 3.  Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection.

Authors:  Lucio G Costa; Rian de Laat; Khoi Dao; Claudia Pellacani; Toby B Cole; Clement E Furlong
Journal:  Neurotoxicology       Date:  2013-09-04       Impact factor: 4.294

4.  Paraoxonases-1, -2 and -3: What are their functions?

Authors:  Clement E Furlong; Judit Marsillach; Gail P Jarvik; Lucio G Costa
Journal:  Chem Biol Interact       Date:  2016-05-26       Impact factor: 5.192

Review 5.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

Review 6.  Oxidative Stress in Atherosclerosis.

Authors:  Ajoe John Kattoor; Naga Venkata K Pothineni; Deepak Palagiri; Jawahar L Mehta
Journal:  Curr Atheroscler Rep       Date:  2017-09-18       Impact factor: 5.113

7.  Paraoxonase 2 decreases renal reactive oxygen species production, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of NADPH oxidase.

Authors:  Yu Yang; Yanrong Zhang; Santiago Cuevas; Van Anthony Villar; Crisanto Escano; Laureano D Asico; Peiying Yu; David K Grandy; Robin A Felder; Ines Armando; Pedro A Jose
Journal:  Free Radic Biol Med       Date:  2012-05-23       Impact factor: 7.376

8.  Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study.

Authors:  Gerard Aragonès; Marta Guardiola; María Barreda; Judit Marsillach; Raúl Beltrán-Debón; Anna Rull; Bharti Mackness; Michael Mackness; Jorge Joven; Josep M Simó; Jordi Camps
Journal:  J Lipid Res       Date:  2011-02-17       Impact factor: 5.922

9.  Paraoxonase 2 attenuates macrophage triglyceride accumulation via inhibition of diacylglycerol acyltransferase 1.

Authors:  Mira Rosenblat; Raymond Coleman; Srinivasa T Reddy; Michael Aviram
Journal:  J Lipid Res       Date:  2008-12-16       Impact factor: 5.922

10.  Effect of quercetin on paraoxonase 2 levels in RAW264.7 macrophages and in human monocytes--role of quercetin metabolism.

Authors:  Christine Boesch-Saadatmandi; Renata Toedter Pospissil; Anne-Christin Graeser; Raffaella Canali; Inka Boomgaarden; Frank Doering; Siegfried Wolffram; Sarah Egert; Manfred James Mueller; Gerald Rimbach
Journal:  Int J Mol Sci       Date:  2009-09-23       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.